about
Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid.Clinical outcomes and therapeutic strategy in patients with acute myocardial infarction according to renal function: data from the Korean Acute Myocardial Infarction Registry.Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failureRelationship between obesity and N-terminal brain natriuretic Peptide level as a prognostic value after acute myocardial infarction.Effect of valsartan on N-terminal pro-brain natriuretic Peptide in patient with stable chronic heart failure: comparison with enalaprilDecreased Glomerular Filtration Rate is an Independent Predictor of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionDetermination of safe contrast media dosage to estimated glomerular filtration rate ratios to avoid contrast-induced nephropathy after elective percutaneous coronary intervention.Fractional flow reserve versus angiography in left circumflex ostial intervention after left main crossover stenting.The impact of moderate to severe renal insufficiency on patients with acute myocardial infarction.Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery DiseaseComparing two-stent strategies for bifurcation coronary lesions: which vessel should be stented first, the main vessel or the side branch?The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation.Impact of high-normal blood pressure measured in emergency room on adverse cardiac events in acute myocardial infarction.Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stentsImpact of home-based exercise training with wireless monitoring on patients with acute coronary syndrome undergoing percutaneous coronary intervention.The efficacy of the cystatin C based glomerular filtration rate in the estimation of safe contrast media volume.Clinical Outcomes in Patients with Deferred Coronary Lesions according to Disease Severity Assessed by Fractional Flow Reserve.Efficacies of the new paclitaxel-eluting Coroflex Please stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please and Taxus (ECO-PLEASANT) trial: study rationale and design.Comparison of sirolimus and paclitaxel-eluting stents for complex coronary lesions: an intravascular ultrasound study.Long-term outcomes of intravascular ultrasound-guided implantation of bare metal stents versus drug-eluting stents in primary percutaneous coronary interventionLate-acquired incomplete stent apposition: morphologic characterization.Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation.Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: the comparison of efficacy between COroflex PLEASe ANd Taxus stent (ECO-PLEASANT) randomized controlled trial.Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study.Fever after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction is associated with adverse outcomes.A case of intra- and extra-mural hematomas during recanalization for chronic total occlusion.Extensive late-acquired incomplete stent apposition after sirolimus-eluting stent implantation.Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.Zotarolimus-eluting stent-induced hypersensitivity pneumonitis.Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent.Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial.Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value.Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.Anatomic and functional evaluation of bifurcation lesions undergoing percutaneous coronary intervention.A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
P50
Q30841001-278C44FA-CEEA-4FBC-A308-73ABB1A7007BQ33362882-2EFF66FE-EF55-484C-BE08-CD075A1ED0DFQ34102097-A4223C37-03D9-4ABF-8044-410890DD7E7AQ34434691-CA880142-90C2-4EA1-B843-42DF80874A69Q34648756-8976807C-1801-411E-A2BE-AC6C7189341AQ34993743-6AD6C0E0-AB60-484C-9A05-27394707C80DQ35048384-B0DF2531-8080-4CA2-926E-A2581E6B1388Q35094779-E8D9E0F5-7471-419A-8355-CC4FBE40162FQ35094783-D977D642-1D35-475B-A3DF-E6F75BBAC654Q35110347-6C301F3B-7772-4595-A807-FA87AFC24204Q35158769-9008CC51-AEBC-41B1-B761-1E02D0304B9EQ35639351-CDE8C708-BCC2-401D-805A-C1A23252ACFDQ35794782-986139FD-14DD-4701-BE4B-1B0B493D10C4Q36015912-7225B566-BD50-44C6-A83E-634402F24CEDQ36528924-1D21C60F-E37B-4B8C-A13B-B54716DBFE91Q36742331-8F65EED7-8ED3-41E9-8F11-5D3F4068CFE6Q37256685-FC8930E3-0FDF-434A-8400-1A63595CE809Q37404927-10A83BF4-5F1E-490C-B0B8-BEAD4D423FEAQ37413031-480C1ED2-07DE-4178-B192-6A837EAD6136Q37445290-4B3F73B9-F285-4CB1-87F5-F086A6711EB9Q37598827-27B3F39E-2445-4333-8141-57372B8CA1F7Q37611213-327DC11F-40F9-4F73-8AA7-7F0275918C23Q37642212-41440850-FDC0-4A78-B1BB-70B53967ED40Q38443515-3FDE5E99-7483-4C44-ADCD-10768A34D4FBQ38450931-83E17B2E-8F8D-4409-AF59-1AE934676332Q38461668-36F047A8-81B3-4267-B7CE-705917F8587DQ40226625-4C3892DE-4DAC-450C-9434-2A9AE8AD8D10Q41438507-22C93ED4-EE0F-427A-AFE8-FC43F8610846Q41821054-B6F14927-2E15-4089-B893-C4AEA8F3989FQ42621457-278B55A4-F9BD-4EBF-9974-D72E6FB88ABAQ42715869-2B52890C-AD05-4E3B-9BA6-06EB9535692CQ42853401-E721C2F4-3BEE-4E9B-B1F2-5BAD29853379Q42861998-3EDDCC53-6F63-4943-8BD8-E052EDC840C8Q42918477-9B73CD5F-A930-418D-9720-DD2B4B072E44Q43009309-B59E9477-40C8-4FA0-B2A4-5E1F6576EC8AQ43015474-5F79BFBC-CDFF-426E-B7FB-614C2B5D5280Q43058168-184DAB96-65D7-4A4B-973B-3E36A5714C92Q43091507-570A66AB-150E-43E7-8BBF-47EAE4B6EBF6Q43103451-FADCCDA7-B4EF-478E-932B-232C371EB40AQ43128835-F55196C9-735A-4008-83AB-5565953C5000
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Seung-Ho Hur
@ast
Seung-Ho Hur
@en
Seung-Ho Hur
@es
Seung-Ho Hur
@nl
Seung-Ho Hur
@sl
type
label
Seung-Ho Hur
@ast
Seung-Ho Hur
@en
Seung-Ho Hur
@es
Seung-Ho Hur
@nl
Seung-Ho Hur
@sl
prefLabel
Seung-Ho Hur
@ast
Seung-Ho Hur
@en
Seung-Ho Hur
@es
Seung-Ho Hur
@nl
Seung-Ho Hur
@sl
P108
P1153
P106
P1153
34570274500
55413455700
55566555200
55595986400
55641121000
P21
P31
P496
0000-0002-3895-1915
P569
2000-01-01T00:00:00Z